With the mission to further Taiwan’s biomedicine industry, CDIB Capital Group (CDIB), a subsidiary of China Development Financial (CDF, TWSE: 2883) has invested in the establishment of a “biomedicine investment ecosystem" and deployed a dedicated cross-strait healthcare investment team to satisfy the needs of the industry in terms of capital-raising, industry development and expansion of international market.
CDIB currently manages three healthcare funds, including one RMB-denominated fund, and two NTD-denominated funds. Along with CDIB’s long-term support for healthcare investments, the AUM (asset under management) has reached in excess of NT$10bn. The Healthcare Fund II (NTD) has been oversubscribed, exceeding the planned size of NT$3bn, and will be launched in September for investment deployment.
According to James Ho, Head of CDIB’s Greater Health Business Group and Chairman of CDIB Capital Health Ventures, “the NT$10-bn-AUM milestone symbolizes CDIB’s capacity to work across countries and facilitate cross-industry collaborations within manufacturing sectors.” With over 60 years of investment experiences, CDIB ‘s four core missions have transitioned from policy-oriented investments, entrepreneurship, sharing prosperity to expanding international business in the era of new globalized economy. In addition to capital-raising, the ecosystem will play a role in talent cultivation, information exchange, and act as a go-between for different players.”
James Ho also said that “in the post-COVID-19 era, the biomedicine industry will take center stage again and a new five-year upcycle will begin.” CDIB will grasp for the opportunity to guide capital into the biomedicine industry, and leverage international institutions, market mechanisms and capital to speed up Taiwan’s integration with the world.
CDIB is dedicated to introducing both domestic and international advanced biomedicine technologies and products to the healthcare markets across the Greater China market. In addition, CDIB also helps the Greater China healthcare industry to innovate, integrate and, ultimately, commercialize outcomes to the global market. After years of team-building, strategy planning and resource integration, CDIB now plays a key role in industry development and international integration
“Talent cultivation is also an integral part of the biomedicine industry investment chain,” said James Ho. Nurturing dedicated healthcare investment professionals is challenging and talents from various backgrounds are in high demand. CDIB boasts the diversity of its team comprised of professionals from medical, medical engineering, biology, chemistry, pharmacology, database management and applications, life sciences, accounting, economics, and finance fields. The diversity is the key for CDIB to conduct successful cross-disciplinary and cross-industry investments.
